Skip to Content

Generic Ubrelvy Availability

Last updated on July 7, 2021.

Ubrelvy is a brand name of ubrogepant, approved by the FDA in the following formulation(s):

UBRELVY (ubrogepant - tablet;oral)

  • Manufacturer: ALLERGAN
    Approval date: December 23, 2019
    Strength(s): 50MG [RLD], 100MG [RLD]

Has a generic version of Ubrelvy been approved?

No. There is currently no therapeutically equivalent version of Ubrelvy available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ubrelvy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Tablet formulation for CGRP active compounds
    Patent 10,117,836
    Issued: November 6, 2018
    Assignee(s): Merck Sharp & Dohme Corp.

    The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “Ra” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

    Patent expiration dates:

    • January 30, 2035
      ✓ 
      Drug product
  • Piperidinone carboxamide azaindane CGRP receptor antagonists
    Patent 8,754,096
    Issued: June 17, 2014
    Assignee(s): Merck Sharp & Dohme Corp.

    The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

    Patent expiration dates:

    • July 19, 2032
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Piperidinone carboxamide azaindane CGRP receptor antagonists
    Patent 8,912,210
    Issued: December 16, 2014
    Assignee(s): Merck Sharp & Dohme Corp.

    The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

    Patent expiration dates:

    • November 10, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Piperidinone carboxamide azaindane CGRP receptor antagonists
    Patent 9,499,545
    Issued: November 22, 2016
    Assignee(s): Merck Sharp & Dohme Corp.

    The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

    Patent expiration dates:

    • November 10, 2031
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Piperidinone carboxamide azaindane CGRP receptor antagonists
    Patent 9,833,448
    Issued: December 5, 2017
    Assignee(s): Merck Sharp & Dohme Corp.

    The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

    Patent expiration dates:

    • November 10, 2031
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • December 23, 2024 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.